Cite
Optimal use of the 131-I-metaiodobenzylguanidine and cisplatin combination in advanced neuroblastoma.
MLA
Mastrangelo, Renato, et al. “Optimal Use of the 131-I-Metaiodobenzylguanidine and Cisplatin Combination in Advanced Neuroblastoma.” Journal of Neuro-Oncology, vol. 31, no. 1/2, Jan. 1997, pp. 153–58. EBSCOhost, https://doi.org/10.1023/A:1005770405844.
APA
Mastrangelo, R., Tornesello, A., Lasorella, A., Iavarone, A., Mastrangelo, S., Riccardi, R., Diociaiuti, L., Rufini, V., Pession, A., & Troncone, L. (1997). Optimal use of the 131-I-metaiodobenzylguanidine and cisplatin combination in advanced neuroblastoma. Journal of Neuro-Oncology, 31(1/2), 153–158. https://doi.org/10.1023/A:1005770405844
Chicago
Mastrangelo, Renato, Assunta Tornesello, Anna Lasorella, Antonio Iavarone, Stefano Mastrangelo, Riccardo Riccardi, Luca Diociaiuti, Vittoria Rufini, Andrea Pession, and Luigi Troncone. 1997. “Optimal Use of the 131-I-Metaiodobenzylguanidine and Cisplatin Combination in Advanced Neuroblastoma.” Journal of Neuro-Oncology 31 (1/2): 153–58. doi:10.1023/A:1005770405844.